Heghine Khachatryan: Homocysteine – A Small Molecule with Big Clinical Consequences
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Homocysteine: a small molecule with big clinical consequences
Homocysteine is an amino acid formed during the metabolism of methionine, which we obtain from protein-rich foods (eggs, meat, fish, cheese, rice, soy, etc.). On its way through metabolic pathways, homocysteine should either be converted to glutathione – our key intracellular antioxidant – or to SAMe (S-adenosylmethionine), a universal methyl donor involved in hundreds of reactions.
Both pathways depend on adequate levels of specific cofactors:
- For homocysteine → glutathione: vitamins B2, B6 and zinc
- For homocysteine → SAMe: vitamins B2, B6, B9, B12, zinc, magnesium and trimethylglycine (TMG, betaine)
When these cofactors are deficient, the reactions slow down, homocysteine accumulates, and we face hyperhomocysteinaemia. In addition to nutritional deficiency, functionally significant variants of the MTHFR gene can impair conversion of folic acid to methylfolate and further disturb homocysteine metabolism.
From a clinical perspective, persistently elevated homocysteine (ideally we aim for <8–9 µmol/L; >20 µmol/L is considered high risk) is associated with:
- Ischaemic stroke
- Alzheimer’s and other dementias
- Parkinson’s disease
- Schizophrenia and other neuropsychiatric disorders
- Atherosclerosis and cardiovascular disease
- Osteoporosis
- Adverse pregnancy outcomes
What can we do in practice?
- Measure homocysteine in appropriate risk groups.
- Assess and correct deficiencies of B-group vitamins, zinc and magnesium (through diet and, when necessary, supplementation).
- Consider the impact of smoking, chronic stress and polypharmacy on micronutrient status.
- In selected cases, evaluate for MTHFR variants and adapt folate therapy (e.g. methylfolate) accordingly.
Homocysteine is a simple marker that sits at the intersection of nutrition, genetics and vascular risk. It deserves more attention both in routine clinical practice and in patient education.”

Stay informed with Hemostasis Today.
-
Nov 3, 2026, 16:57Ahmed Alotaibi: Which Macrophage Receptor ‘eats’ anti-E and Anti-K Coated RBCs?
-
Nov 3, 2026, 16:53Jan Sloves: Key Factors for Achieving Durable Patency in Advanced Venous Stenting
-
Nov 3, 2026, 16:45Nina Weber: Review on Kidney Injury After Stem Cell Transplantation
-
Nov 3, 2026, 16:36Chris Baugh: EMplify Podcast Explores Antithrombotic Associated Bleeding in the Emergency Department
-
Nov 3, 2026, 16:32Carlo Zaninetti: Highlights from the XXIX Congress of the Italian Society on Haemostasis and Thrombosis
-
Nov 3, 2026, 15:10Lady Joan Branson’s Story – The Hidden Danger of Hospitalization
-
Nov 3, 2026, 14:38Emna Hammami: Exploring the Haemophilia Treatment Landscape at the EHC New Technologies Conference
-
Nov 3, 2026, 14:20EHC Marks the Final Edition of Its New Technologies Conference in Bucharest
-
Nov 3, 2026, 14:15Rhiannon Morris: Awarded CASS Foundation Travel Grant to Present Research at ASH 2026